EE160 Tepotinib for the Treatment of Adult Patients with Metastatic Non-Small Cell Lung Cancer Harboring METEX14 Skipping Alterations: A US Cost-Effectiveness Analysis.
Saved in:
| Title: | EE160 Tepotinib for the Treatment of Adult Patients with Metastatic Non-Small Cell Lung Cancer Harboring METEX14 Skipping Alterations: A US Cost-Effectiveness Analysis. |
|---|---|
| Authors: | Yang, M1 (AUTHOR), Sachdev, R2 (AUTHOR), Stargardter, M2 (AUTHOR), Tosh, J3 (AUTHOR), Vioix, H4 (AUTHOR) |
| Source: | Value in Health. 2022 Supplement, Vol. 25 Issue 7, pS365-S365. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 10983015 |
|---|---|
| DOI: | 10.1016/j.jval.2022.04.409 |
